Bone Biologics Corp
BBLG evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BBLG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BBLG
Bone Biologics Corp (BBLG) is a clinical-stage biotechnology company developing a bone graft substitute product candidate for spinal fusion procedures, currently facing significant financial uncertainty and relying on future financing to continue operations.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 6 clinical trials · 1 catalyst for Bone Biologics Corp.
Bone Biologics Corp (BBLG) is a clinical-stage biotechnology company developing a bone graft substitute product candidate for spinal fusion procedures, currently facing significant financial uncertainty and relying on future financing to continue operations.
- Bone Biologics is a clinical-stage company with a limited operating history and no approved products, making it difficult to evaluate its business prospects [sec · filed 2025-06-24].
- The company reported a net loss of -$0.8M and shareholders' equity of $5.4M as of 2026-06-30 [sec].
- The company has expressed substantial doubt about its ability to continue as a going concern and requires additional capital to fund operations and clinical trials [sec · filed 2026-07-17].
- The company has an upcoming catalyst: Phase 3 Topline data for MDT-0123 in lumbar vertebral fusion in Japan, expected on 2028-03-31 [upcoming catalysts].
- The company's cash position was $3.6M as of September 30, 2024, with available cash expected to cover operations only into the second quarter of 2025 [sec_mda · as of 2024-11-14].
What works
- The company has a defined clinical catalyst with a Phase 3 Topline readout for MDT-0123 scheduled for 2028-03-31, targeting patients requiring lumbar vertebral fusion in Japan [upcoming catalysts].
- The company has an existing patent portfolio and intends to use proceeds from offerings to maintain and extend it [sec · filed 2026-07-17].
What to weigh
- The company has a limited operating history and minimal assets, with no significant financial resources, raising substantial doubt about its ability to continue as a going concern [sec · filed 2025-06-24].
- The company requires substantial additional capital to fund operations and clinical development, and there is no assurance that such financing will be available on acceptable terms [sec_mda · as of 2024-11-14].
- Cash of $3.6M as of September 30, 2024 was only expected to cover operational needs into the second quarter of 2025, indicating a tight cash runway [sec_mda · as of 2024-11-14].
- The company faces risks of being unable to maintain Nasdaq listing compliance, which could impact its ability to raise capital [sec · filed 2026-07-17].
From the filings
Quoted directly from source documents.
The company has a limited operating history and going concern risk.
“We have a limited operating history, and there is a risk that we will be unable to continue as a going concern.”
SEC filings · June 24, 2025
The company requires $5 million to complete first-in-man studies and $24 million for FDA approval.
“We anticipate that we will require approximately $5 million to complete first-in-man studies, and an estimated additional $24 million in scientific expenses to achieve FDA approval, if possible, for a spine interbody fusion indication.”
SEC MD&A · May 14, 2024
Cash position and runway as of September 30, 2024.
“At September 30, 2024 and December 31, 2023, we had cash of $3,566,426 and $3,026,569, respectively. Available cash is anticipated to cover our operational needs into the second quarter of 2025.”
SEC MD&A · November 14, 2024
Catalyst timeline
- 2028-03-31 · Phase3_Topline — Phase 3 Topline data for MDT-0123 clinical trial targeting patients who require lumbar vertebral fusion in Japan.
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — The company has expressed substantial doubt about its ability to continue as a going concern due to limited operating history and minimal assets [sec · filed 2025-06-24].
- Capital requirement risk — The company needs substantial additional capital to fund operations and clinical trials, with no assurance of financing on acceptable terms [sec_mda · as of 2024-11-14].
- Cash runway constraint — Cash of $3.6M as of September 30, 2024 was only expected to cover operations into Q2 2025, indicating a tight runway [sec_mda · as of 2024-11-14].
- Nasdaq listing compliance — Failure to maintain Nasdaq listing standards could limit the company's ability to raise capital [sec · filed 2026-07-17].
What to watch
- Ability to raise additional capital through debt or equity financing to extend cash runway beyond Q2 2025 [sec_mda · as of 2024-11-14].
- Progress and results of the Phase 3 clinical trial for MDT-0123 in Japan, with topline data expected in 2028 [upcoming catalysts].
- Any updates on Nasdaq listing compliance and the company's ability to maintain its listing [sec · filed 2026-07-17].
- Potential strategic alliances or partnerships that could provide funding or development support [sec_mda · as of 2024-11-14].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Bone Biologics Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Bone Biologics Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.13 · 0% dilution
Lead: Phase 1
1 candidate
1 upcoming, next in ~579d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Dec 2025Institutional holders
3
Total value held
$32K
| Holder | Shares | Value |
|---|---|---|
| two sigma investments, lp | 11,083 | $16K |
| citadel advisors llc | 10,844 | $16K |
| bank of america corp /de/ | 14 | $20 |
Short Interest
as of May 20, 2026- % of float
- 0.6%
- Days to cover
- 0.9
- Shares short
- 10,427
- Daily short volume (Jun 26, 2026)
- 27.2%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BBLG short interestGovernance
Frequently asked questions
What is the AI investment thesis for Bone Biologics Corp?
Bone Biologics Corp (BBLG) is a clinical-stage biotechnology company developing a bone graft substitute product candidate for spinal fusion procedures, currently facing significant financial uncertainty and relying on future financing to continue operations.
What is Bone Biologics Corp's lead drug candidate?
Bone Biologics Corp's most advanced tracked candidate is nb1 (Phase 1) for Lumbar spinal fusion.
What is Bone Biologics Corp's next catalyst?
Bone Biologics Corp's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: MDT-0123 Clinical Trial Targeting Patients Who Require Lumbar Vertebral Fusion in Japan" — expected March 31, 2028.
Who is the CEO of Bone Biologics Corp?
Mr. Jeffrey Frelick is the chief executive officer of Bone Biologics Corp (BBLG).
Where is Bone Biologics Corp headquartered?
Bone Biologics Corp (BBLG) is headquartered in Burlington, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.